Characteristics of 163 included trials
| All trials n (%) | Non-RIT trials n (%) | RIT trials n (%) | |
| Total n=163 | Total n=132 | Total n=31 | |
| Journal | |||
| New England Journal of Medicine | 64 (39) | 53 (40) | 11 (35) |
| Lancet | 63 (39) | 49 (367) | 14 (45) |
| JAMA | 23 (14) | 21 (16) | 2 (6) |
| BMJ | 8 (5) | 6 (5) | 2 (6) |
| Annals of Internal Medicine | 5 (3) | 3 (2) | 2 (6) |
| Year* | |||
| 2011 | 12 (7) | 10 (8) | 2 (6) |
| 2012 | 25 (15) | 18 (14) | 7 (23) |
| 2013 | 34 (21) | 31 (23) | 3 (10) |
| 2014 | 22 (14) | 14 (11) | 8 (26) |
| 2015 | 43 (26) | 36 (27) | 7 (23) |
| 2016 | 27 (17) | 23 (17) | 4 (13) |
| Top specialties | |||
| Infectious diseases | (25) | (24) | (26) |
| Haematology/Oncology | (21) | (17) | (39) |
| Cardiology | (17) | (19) | (6) |
| Pulmonary/Critical care | (13) | (14) | (6) |
| Endocrine | (6) | (7) | (3) |
| Primary outcome measured as: | |||
| Absolute risk difference | 114 (70) | 92 (70) | 22 (71) |
| Mean | 26 (16) | 23 (17) | 3 (10) |
| HR | 13 (8) | 9 (7) | 4 (13) |
| Relative risk difference | 8 (5) | 7 (5) | 1 (3) |
| OR | 2 (1) | 1 (1) | 1 (3) |
Additional characteristics of the trials can be found in Aberegg et al. 15
*2011 and 2016 were incomplete years.
RIT, reduced intensity therapy.